高级检索
生玉平, 马晓迎, 孙福云, 杨星梦, 王娜, 张浩然, 徐海平. 血小板衍生生长因子、Beclin1与血液透析患者血管钙化的关系[J]. 实用临床医药杂志, 2022, 26(21): 60-64. DOI: 10.7619/jcmp.20221842
引用本文: 生玉平, 马晓迎, 孙福云, 杨星梦, 王娜, 张浩然, 徐海平. 血小板衍生生长因子、Beclin1与血液透析患者血管钙化的关系[J]. 实用临床医药杂志, 2022, 26(21): 60-64. DOI: 10.7619/jcmp.20221842
shu
SHENG Yuping, MA Xiaoying, SUN Fuyun, YANG Xingmeng, WANG Na, ZHANG Haoran, XU Haiping. Correlations of platelet-derived growth factor and Beclin1 with vascular calcification in hemodialysis patients[J]. Journal of Clinical Medicine in Practice, 2022, 26(21): 60-64. DOI: 10.7619/jcmp.20221842
Citation: SHENG Yuping, MA Xiaoying, SUN Fuyun, YANG Xingmeng, WANG Na, ZHANG Haoran, XU Haiping. Correlations of platelet-derived growth factor and Beclin1 with vascular calcification in hemodialysis patients[J]. Journal of Clinical Medicine in Practice, 2022, 26(21): 60-64. DOI: 10.7619/jcmp.20221842
shu

血小板衍生生长因子、Beclin1与血液透析患者血管钙化的关系

Correlations of platelet-derived growth factor and Beclin1 with vascular calcification in hemodialysis patients

    摘要
  • 摘要:
    目的 探讨血清血小板衍生生长因子-BB（PDGF-BB）、自噬相关分子Beclin1水平与行维持性血液透析（MHD）患者血管钙化（VC）的相关性。
    方法 选取100例MHD患者为MHD组，100例健康者为对照组，比较2组血清PDGF-BB、Beclin1水平。按腹主动脉钙化评分（AACS）将MHD患者分为钙化组（48例）和非钙化组（52例）。分析MHD患者发生VC的影响因素；分析血清PDGF-BB、Beclin1水平预测MHD患者VC的价值。
    结果 MHD组血清PDGF-BB水平（90.57±31.64）pg/mL高于对照组（41.78±13.83）pg/mL，血清Beclin1水平（2.02±0.68）ng/mL低于对照组（3.09±1.04）ng/mL，差异有统计学意义（P < 0.05）。血磷、PDGF-BB、血钙、TG是影响MHD患者发生VC的危险因素（P < 0.05），Beclin1是影响MHD患者发生VC的保护因素（P < 0.05）。血清PDGF-BB、Beclin1水平预测MHD患者VC的曲线下面积（AUC）分别为0.885、0.832；血清PDGF-BB、Beclin1水平联合预测MHD患者VC的AUC为0.932，敏感度为85.4%，特异度为92.3%。
    结论 MHD患者血清PDGF-BB水平较高，Beclin1水平较低，两者均与VC相关。血清PDGF-BB、Beclin1联合预测可能有助于临床预防、评估MHD患者并发VC。

     

    Abstract:
    Objective To investigate the correlations of serum platelet-derived growth factor-BB (PDGF-BB) and autophagy-related molecule Beclin1 with vascular calcification (VC) in patients undergoing maintenance hemodialysis (MHD).
    Methods A total of 100 MHD patients were selected as MHD group, and 100 healthy people were selected as control group. The levels of serum PDGF-BB and Beclin1 were compared between the two groups. According to Abdominal Aortic Calcification Score (AACS), MHD patients were divided into calcification group (48 cases) and non-calcification group (52 cases). The influencing factors of VC in MHD patients were analyzed; the value of serum PDGF-BB and Beclin1 levels in predicting VC in MHD patients were analyzed.
    Results The level of serum PDGF-BB in the MHD group(90.57±31.64) pg/mL was significantly higher than that in the control group(41.78±13.83) pg/mL, and the level of Beclin1 in MHD group(2.02±0.68) ng/mL was significantly lower than that in the control group(3.09±1.04) ng/mL (P < 0.05). Blood phosphorus, PDGF-BB, blood calcium and TG were the risk factors for VC in MHD patients (P < 0.05), and Beclin1 was a protective factor for VC in MHD patients (P < 0.05). The area under the curve (AUC) of serum PDGF-BB and Beclin1 levels in predicting VC in MHD patients were 0.885 and 0.832, respectively; the AUC of serum PDGF-BB and Beclin1 in combination to predict VC in MHD patients was 0.932, the sensitivity was 85.4%, and the specificity was 92.3%.
    Conclusion The serum PDGF-BB level is higher and Beclin1 level is lower in MHD patients, both of them were related to VC. The combined prediction of serum PDGF-BB and Beclin1 may help to prevent and evaluate VC in MHD patients.

     

    • HTML全文
    • 参考文献(20)
    • 相关文章
    • 施引文献
  • 资源附件(0)

/

返回文章
返回